Alexis Visotcky

Jul 27, 2024 | medrxiv.org | Muhammad Hammad |Alexis Visotcky |Rodney A. Sparapani |Jacquelyn P. Kulinski

The authors have declared no competing interest. NCT04121741Research reported in this publication was supported by the National Center For Complementary & Integrative Health of the National Institutes of Health under Award Number R33AT010680. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Dec 22, 2023 | onlinelibrary.wiley.com | Alexis Visotcky |Anjishnu Banerjee |Mohammed Aldakkak |Susan Tsai

1 INTRODUCTION Pancreatic adenocarcinoma (PDAC) is a highly aggressive malignancy and will become the second leading cause of cancer-related death in the United States by 2030.1, 2 Many patients with PDAC present with clear radiological evidence of metastatic disease.